• About Antengene

    About Antengene

    Antengene is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world.We distinguish ourselves through our industry-leading R&D capabilities and differentiated strategic approach to developing novel oncology therapies. Our vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies. Antengene?was listed on the Main Board of The Stock Exchange on 20th December 2020, SEHK: 6996.HK.

    By efficiently utilizing our resources and leveraging our outstanding capability in target selection and differentiated discovery and development strategy, we have established a robust and highly innovative pipeline of 13 drug assets focused on oncology and other indications, including two late-stage clinical assets and four early-stage clinical assets, and we have submitted 5 new drug applications (NDA) in multiple markets in Asia Pacific. In addition, leveraging our strong R&D capabilities, we are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have first-in-class potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.

    Since establishment, we have built a solid research & development infrastructure and clinical development capabilities across the Asia Pacific (APAC). We are expanding our own commercial teams in APAC in anticipation of near term launches in multiple countries and regions. Our commercial teams are composed of leaders from MNCs with rich global and regional commercialization experience as well as local field force who have in-depth understanding of dynamics of each market.

    Management Team

    1. Kevin Lynch, M.D.

      Kevin Lynch, M.D.

      Chief Medical Officer

      Dr. Lynch has almost 30 years of experience in R&D in the pharmaceutical industry and a strong track record in clinical development and medical affairs.
      Dr. Lynch was Vice President at Celgene where he led the clinical development and medical affairs in multiple countries and regions. Before that, he was the Medical Director of Oncology at Novartis Pharmaceuticals Australia.
      Dr. Lynch has been closely involved in the clinical development of multiple transformational cancer therapies, including Glivec?, Tasigna?, Zometa?, Femara?, Revlimid?, Pomalyst?, and Vidaza?. With his deep expertise and wealth of experience in the pharmaceutical industry, Dr. Lynch has published in many leading journals, including Annals of Internal Medicine, Nature Reviews Cancer, British Journal of Cancer, Clinical Cancer Research, Journal of Clinical Oncology, and Blood, etc.

    2. Jay Mei, M.D., Ph.D.

      Jay Mei, M.D., Ph.D.

      Founder, Chairman and CEO

      Dr. Mei has over 25 years of experience in clinical research and development of oncology therapeutics globally. He has published over 70 publications and is the co-inventor of multiple patents. In the 1990s, Dr. Mei dedicated himself to extensive cancer research at the National Cancer Institute in the United States. In 2001, Dr. Mei joined as a Principal Scientist in the oncology team in the drug discovery division and Associate Director at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. From 2006, Dr. Mei worked as a Senior Director at Novartis Oncology, part of the Innovative Medicines division of Novartis AG. From 2008 to 2017, he served as an Executive Director of the clinical development department at Celgene (now part of Bristol-Myers Squibb). At Celgene, Dr. Mei was one of the leading members in the clinical development of multiple blockbuster drugs that represent the most significant part of Celgene’s portfolio today, including REVLIMID?, which is among the best-selling oncology therapies worldwide, and was also involved in the clinical development of POMALYST?, also one of the best-selling oncology drugs worldwide, and IDHIFA?, a first-in-class drug for the treatment of acute myeloid leukemia. Dr. Mei was involved in the management of Antengene since April 2017. Dr. Mei also currently holds adjunct professorship at the Baruch S. Blumberg Institute.

      Dr. Mei received his Doctor of Medicine (M.D.) degree from Hunan Medical University (now XiangYa School of Medicine of Central South University) and obtained his Doctor of Philosophy (Ph.D.) degree in pharmacology and toxicology from the University of Maryland. Dr. Mei has been a member of the American Society of Hematology since 2006.

    3. Bo Shan, Ph.D.

      Bo Shan, Ph.D.

      Chief Scientific Officer

      Dr. Shan has nearly 20 years of global pharmaceutical industry experience and has led interdisciplinary teams to deliver multiple IND and NDA programs.
      In his previous role at Antengene as Corporate Vice President, Dr. Shan led the discovery, early development, and CMC programs. During his tenure, Dr. Shan assembled highly effective discovery, CMC and manufacturing teams, and built a pre-clinical pipeline of 6 assets for the company. Prior to Antengene, Dr. Shan led the construction and validation of Drug manufacturing facility which successfully passed GMP inspection.

    4. John F. Chin, MBA

      John F. Chin, MBA

      Chief Business Officer

      Mr. Chin has 30 years of experience in the pharmaceutical industry, and was the former Country General Manager at Celgene China,leading a cross-functional team to support the development, approval and commercialization of Celgene assets in China.

      Mr. Chin’s involvement was instrumental in the commercial launch and lifecycle management of REVLIMID?, one of the industry’s most successful oncology products globally.

    5. Donald Andrew Lung, J.D., MBA

      Donald Andrew Lung, J.D., MBA

      Chief Financial Officer

      Mr. Lung has more than 16 years of experience in investment banking and public equities, including at Goldman Sachs and BFAM Partners.

      Mr. Lung invested across sectors, including in the healthcare and biotech industry at BFAM Partners.

    6. Yiteng Liu, M.Sc.

      Yiteng Liu, M.Sc.

      Chief Operating Officer

      Mr. Liu has over 10 years of experience in various capacities at multi-national companies in investment and industry consulting.

      Mr. Liu led RMB2.5 billion investment in healthcare projects at CITIC Industrial Investment Group Corp., Ltd. while serving as the general manager of the strategic development department at CITIC Senior Living Ltd.

    7. Yijun Yang, Sc.D., Ph.D.

      Yijun Yang, Sc.D., Ph.D.

      Corporate Vice President, Alliance Management and Clinical Enabling Functions

      Dr. Yang has 20 years of experience in the pharmaceutical industry and held positions at Harvard University and multiple global pharmaceutical companies.

      Dr. Yang participated in the clinical development approvals of multiple therapeutics, including INCIVEK? (telaprevir), TORISEL? (temsirolimus) and KANUMA? (sebelipase alfa).

    8. Zhinuan Yu, Ph.D.

      Zhinuan Yu, Ph.D.

      Corporate Vice President, Biometrics & Regulatory Enabling Functions

      Dr. Yu has over 20 years of experience in the pharmaceutical industry and led the statistical support at Celgene for multiple high-priority programs, including thalidomide, lenalidomide, pomalidomide and bb2121 (CAR-T).

    9. Thomas Karalis, B.Sc.

      Thomas Karalis, B.Sc.

      Corporate Vice President, Head of Asia Pacific Region

      Mr. Karalis has over 30 years of experience in the pharmaceutical industry, including as the former General Manager for Celgene East Asia and Vice President & General Manager for Celgene Australia and New Zealand.

      During Mr. Karalis’ tenure at Celgene, multiple regulatory and reimbursement milestones were achieved for core products in APAC markets leading to successful launches of REVLIMID? (lenalidomide), POMALYST? (pomalidomide) and ABRAXANE? (paclitaxel protein-bound particles for injectable suspension).

    10. Shimin Sun, M.D., MPH

      Shimin Sun, M.D., MPH

      Corporate Vice President, Head of Clinical Operations

      Ms. Sun has nearly 20 years of clinical development and clinical trial operations experience in different disease areas, especially in oncology and infectious diseases. She participated, managed and led over 70 clinical trials across Phase I to Phase IV.

      Ms. Sun was involved in many important China registration projects, including HERCEPTIN?, PEGASYS?, PEGINTRON?, TARCEVA? and the first rituximab biosimilar product in China.

    11. Dirk Hoenemann, M.D.

      Dirk Hoenemann, M.D.

      Vice President, Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

      Mr. Hoenemann has over 20 years of experience in clinical research, translational medicine, academia, and the pharmaceutical industry. He published numerous journals and articles in relation to first-in-human initiatives with novel antibody formats in hematological malignancies and solid tumors.

      Mr. Hoenemann made substantial contributions to CAR-T study targeting Lewis-Y antigen.

    Investors

    Company Honor

    China Healthcare Industry Investment and Financing Honor List 2019– Medical and Health Companies with the Highest Investment Value

    2019

    The 4th Healthcare Investment ExcellentList—Annual Best Enterprise in Biopharmaceutical Industry 2020

    2020

    Future Healthcare VB 100 List 2019—TOP10 Best-Performing CEOs

    2019

    Future Healthcare VB 100 List 2019—TOP100

    2019

    CV Awards– The Best Investment Case in the Biopharmaceutical Field of 2019

    2019

    “Hurun” Top 100 Rising Star Enterprises with the Most Investment Value in China– Top 50 Zhejiang

    2018

    Shaoxing City Development Contribution Award 2018

    2018

    The ATG-008 project was selected as a Major Special Project for New Drug Creation in the 13th Five-Year Plan of the Ministry of Science and Technology 2018

    2018

    Antengene was selected as a Leading Introducing and Cultivating Innovation & Entrepreneurship Team in Zhejiang Province

    2019

    The ATG-008 project was selected as a Major Special Project for New Drug Creation in the 13th Five-Year Plan of the Ministry of Science and Technology 2019

    2019

    First Award of 6th Zhejiang China Innovation & Entrepreneurship Competition 2019

    2019

    First Award in Biopharmaceutical Industry of 8th China Innovation & Entrepreneurship Competition 2019

    2019

    China’s Pharmaceutical Innovative Enterprises 2020

    2020

    “The Most Popular New Stock Company Among Investors” at the 5th Annual Awards Ceremony of “Golden Hong Kong Stock”

    2021

    The 10th China Charity Festival “CSR Industry Model Award 2020”

    2021

    Pharmaceutical Innovative Company of China in 2020

    2020

    2019 China Healthcare Industry Investment and Financing Honor List

    2019

    Hurun China Future Unicorns 2019 Q2

    2019

    Hurun China Future Unicorns 2019 Q1

    2019

    China Future Healthcare Rankings 2019 Top 100 Pharma & Biotech Companies

    2019

    Future Medical Top 100 Pengcheng Award Annual Innovative Enterprise CEO in 2019

    2019

    Best Investment Case in Bio-pharmaceutical Industry of China Investment List in 2019

    2019

    Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang Province

    2019

    The Champion of the 8th National Leading Innovation and Entrepreneurship Competition

    2019

    The Champion of the 6th Innovation & Entrepreneurship Competition of Zhejiang Province

    2019

    Dr. Jay Mei won the title of “2020 China Economic News Person · New Economic Leader”

    2020
    三级国产国语三级在线2,午夜三级中文不卡电影,国产三级a在线观看